ClinicalTrials.gg
CompletedNCT00631358Updated Apr 12, 2010Results posted

Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention

A Phase 4 interventional study of Maxidex and No treatment in Sjogren's Syndrome, sponsored by Alcon Research. Completed at 2 sites in Canada. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-12.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Sjogren's Syndrome with a site in Canada — 4 open to participants now, 9 under way, 7 of them phase 3. Sjogren's Syndrome · Canada.

Enrollment
13th of 16
97 · median 389
Started
2008
the only one that year
Phase 4
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
1 of 18
Alcon Research

Among the 18 studies in Sjogren's Syndrome with a site in Canada, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2008, is the only one in phase 4, and was the 1st registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

4 of the 18 studies in Sjogren's Syndrome with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 17 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sjogren's Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.

03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

Keywords

  • Ocular inflammation
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria of Sjorgren's Population:

Inclusion Criteria:

  • 17 years or older
  • LogMar visual acuity of 0.6 or better
  • Ocular inflammation associated with Sjogren's Syndrome

Exclusion Criteria:

  • Has had an adverse reaction to either topical of systemic in the past
  • Has diabetes (type 1 or 2)
  • Has glaucoma or evidence of ocular hypertension in either eye or treatment of either within six months of Visit 1
  • Has worn contact lenses within one week prior to Visit 1
  • Has received ocular prescription therapy in the last 30 days
  • Has active ocular infections or inflammation not associated with Sjogren's Syndrome.
  • Has any finding in the vitreous, macula, retina or choroid that show signs of inflammation and/or any structural change that in the opinion of the investigator is considered abnormal or unstable for that participant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Maxidex

    Maxidex

    Drug: Maxidex

  • Sham comparator
    No treatment

    Healthy normal control group receiving no treatment

    Other: No treatment

Interventions

  • Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily

  • OtherNo treatment

    Healthy normal control group receiving no treatment

06

What researchers measure

Primary outcomes

  1. Change in Levels of Biomarkers After Dosing With Maxidex

    Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.

    Time frame: Baseline to 2 weeks

Secondary outcomes

  1. Correlation Between Biomarker Expression and Ocular Symptoms

    Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).

    Time frame: Baseline to 2 weeks

  2. Correlation Between Biomarker Expression and Tear Film Break up Time

    Correlation factor: TNFmRNA vs. TFBUT (Tear Film Break-up Time)

    Time frame: Baseline to 2 weeks

  3. Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining

    Correlation factor: TNFmRNA vs. NaFl staining

    Time frame: Baseline to 2 weeks

  4. Correlation Between Biomarker Expression and the Schirmer Test

    Correlation factor: TNFmRNA vs. Schirmer

    Time frame: Baseline to 2 weeks

07

Results

Posted Apr 12, 2010

Participant flow

Patients were recruited via flyers, newspaper advertisements, radio advertisements and chart review in the doctors' office.

Participant flow — Overall Study
MilestoneMaxidexNo Treatment
Started5047
Completed4445
Not completed62

Outcome measures

PrimaryChange in Levels of Biomarkers After Dosing With Maxidex

Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.

Time frame:
Baseline to 2 weeks
Reported as:
Mean · ddCt (Delta-Delta-Ct)
Change in Levels of Biomarkers After Dosing With Maxidex
ddCt (Delta-Delta-Ct)MaxidexNo Treatment
Baseline-1.244 ± 1.08-0.29 ± 0.88
2 weeks-0.033 ± 1.06-0.33 ± 0.85
SecondaryCorrelation Between Biomarker Expression and Ocular Symptoms

Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).

Time frame:
Baseline to 2 weeks
Reported as:
Number · Correlation factor
Correlation Between Biomarker Expression and Ocular Symptoms
Correlation factorMaxidexNo Treatment
Correlation Between Biomarker Expression and Ocular Symptoms-0.09-0.10
SecondaryCorrelation Between Biomarker Expression and Tear Film Break up Time

Correlation factor: TNFmRNA vs. TFBUT (Tear Film Break-up Time)

Time frame:
Baseline to 2 weeks
Reported as:
Number · Correlation factor
Correlation Between Biomarker Expression and Tear Film Break up Time
Correlation factorMaxidexNo Treatment
Correlation Between Biomarker Expression and Tear Film Break up Time-0.160.12
SecondaryCorrelation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining

Correlation factor: TNFmRNA vs. NaFl staining

Time frame:
Baseline to 2 weeks
Reported as:
Number · Correlation factor
Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining
Correlation factorMaxidexNo Treatment
Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining-0.05—
SecondaryCorrelation Between Biomarker Expression and the Schirmer Test

Correlation factor: TNFmRNA vs. Schirmer

Time frame:
Baseline to 2 weeks
Reported as:
Number · Correlation Factor
Correlation Between Biomarker Expression and the Schirmer Test
Correlation FactorMaxidexNo Treatment
Correlation Between Biomarker Expression and the Schirmer Test-0.020.07

Adverse events

Collected over Adverse reporting began once the patient enrolled into the study and went on for the duration of the study (6 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maxidex—0/50 (0%)0/50 (0%)
No Treatment—0/47 (0%)0/47 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MaxidexNo TreatmentTotal
<=18 years000
Between 18 and 65 years354176
>=65 years15621
Sex: Female, Male
Sex: Female, Male(Participants)MaxidexNo TreatmentTotal
Female484391
Male246
08

Study locations

2 sites
  • Toronto
    Toronto, Canada
  • Waterloo
    Waterloo, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2008
First posted
Mar 7, 2008
Start
Feb 2008
Primary completionActual
Feb 2009
Results first posted
Apr 12, 2010
Last update
Apr 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00631358
Lead sponsor
Alcon Research
First posted
Mar 7, 2008
Start date
Feb 2008
Primary completion
Feb 2009
Results posted
Apr 12, 2010
Last update
Apr 12, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion